Cardiac Biomarkers Market Snapshot

Key Players

  • Roche Diagnostics (Switzerland)
  • Abbott Laboratories (United States)
  • Siemens Healthineers (Germany)
  • Beckman Coulter (United States)
  • Becton Dickinson and Company (United States)
  • Ortho Clinical Diagnostics (United States)
  • Bio-Rad Laboratories Inc (United States)
  • Randox Laboratories Ltd (United Kingdom)

Market Size

Base Year 2024
$18.38 Bn
CAGR
13.14%
Forecast 2034
$63.17 Bn

Market Segments

By Type
  • Creatine Kinase (CK-MB)
  • Troponins T and Imyoglobin
  • BNPs
  • IMA
  • Others
By Location of Testing
  • Point of Care
  • Laboratory Testing
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis

Market Dynamics

Drivers
  • Increasing prevalence of cardiovascular diseases
  • Advancements in cardiac biomarker testing technologies
Restraints
  • High testing costs
  • Stringent regulatory standards
Opportunities
  • Rising prevalence of cardiovascular diseases
  • Increasing investment in biomarker research
Trends
  • Rising prevalence of cardiovascular diseases
  • Increasing Point of Care testing demand

Market Size

The Cardiac Biomarkers Market size estimated at $20.80 billion in the year 2025, up from $18.38 billion in 2024. By the year 2034, the market is projected to reach $63.17 billion, at a CAGR of 13.1% from 2025 to 2034. This considerable increase in market size over the period is fueled by a rising prevalence of cardiovascular diseases across the globe and the benefits of cardiac biomarkers in the prevention, diagnosis, and therapeutic monitoring of these diseases. Rapid advancements in cardiac biomarker tests, leading to improved accuracy, specificity, and sensitivity, is another contributing factor to this growth. However, the regional share distribution indicated North America holding the largest share at 39.8%, closely followed by Asia Pacific at 28.4%. Europe accounted for 24.4% while Latin America and the Middle East and Africa had the smallest shares at 4.1% and 3.4% respectively.

Key Takeaways

  • By Type - Troponins T and I-Myoglobin held a significant share accounting for notable position in the Cardiac Biomarkers market.
  • By Location of Testing - Laboratory Testing led the sector with a dominate share in Cardiac Biomarkers Market.
  • By Application -Congestive Heart Failure expanded most rapidly accounting for high growth rate in Cardiac Biomarkers Market.
cardiac-biomarkers-market market size

Key Driving Factors

Implementation of the POC Testing

Point-of-care (POC) testing has emerged as a crucial driver in the Cardiac Biomarkers market. These tests provide rapid, immediate results, allowing clinicians to make quick, informed decisions about patient care. In the case of conditions like myocardial infarction where time-sensitive treatments significantly affect outcomes, POC testing for cardiac biomarkers such as troponin and CK-MB can dramatically improve patient prognosis. The consistency in results accuracy delivered by POC compared to laboratory tests is fueling its adoption in healthcare centers, specifically emergency departments, reducing the timeframe from patient presentation to treatment initiation.

Global shift towards Preventive Healthcare

Globally, healthcare systems are making the shift from disease treatment to disease prevention. Cardiac biomarkers provide essential insight into heart health, identifying risks before they develop into serious conditions. Preventative healthcare's goal is to reduce the demand for more invasive and expensive treatments. Risk assessment for cardiovascular diseases using these biomarkers supports healthcare providers develop tailored and targeted prevention strategies for high-risk individuals. This proactive approach to healthcare has driven an increase in the usage of biomarkers as an essential tool in the fight against heart disease.

Market Evolution by Timeline

2019-2023
In 2019-2023, cardiac biomarkers usage expanded due to the higher incidence of cardiovascular diseases in developed countries and emerging economies. As the standard for testing suspected cardiac patients, troponin dominated supply, particularly new generation high sensitivity troponin assays. However, regulations such as the European Union's In Vitro Diagnostic Directive (IVD) limited dissemination due to stringent safety and efficacy requirements. Point of care testing kits gained commercial acceptance due to rapid turnaround times. Pricing trends shifted towards volume-based discounts for large hospital chains. A risk was that over-reliance on troponin could lead to overlooked secondary biomarkers.
2024
In 2024, demand for cardiac biomarkers expanded in Asia-Pacific due to growing awareness of cardiac diseases. Notably, the industry increased in natriuretic peptides as a key biomarker, witnessed as essential for efficient cardiac dysfunction diagnoses. Regulation via the IVD led to more cautious deployment. Wider distribution through Point of Care Testing (POCT) was driven by a need for immediate results in critical patient conditions. Risk-adjusted pricing drove the commercial model, with a growth in volume purchase agreements with small clinics, while isolation of insensitive biomarkers posed a risk.
2025-2029
During 2025-2029, Middle East and African regions is expected to indicate increased usage of cardiac biomarkers due to rising incidences of cardiovascular diseases. Advances in biomarker research might increase Myoglobin and CK-MB in the supplier landscape; yet, their adoption might faced hurdles due to regulatory frameworks like the U.S. FDA's stringent approval process. Commercial models will likely witness a shift towards subscription-based contracts offering limited kits for increased testing frequency. Partnerships between cardiac biomarker developers and pharmaceutical companies may gain popularity.
2030-2034
In the period 2030-2034, the use of cardiac biomarkers in Latin America might expand due to increased investment in healthcare infrastructure. Makers will likely expand their product offerings to include Galectin-3 and ST2 tests, however might face challenges due to the WHO's strict compliance requirements. Remote patient monitoring will likely drive market innovation, allowing regular testing outside the hospital environment. The primary procurement model may lease agreements with diagnostic centers with flexible terms. The risk of data privacy violations might emerge as digital biomarker data management will grow in the period.

Future Market Outlook

Technology Trends

The cardiac biomarkers market has experienced significant developments driven by advancements in technology and regulatory support. In 2021, the American Heart Association published new guidelines emphasizing the importance of cardiac biomarkers in diagnosing heart conditions. Companies like Abbott have introduced products such as the AiVita Biomarker Testing System to enhance early detection of cardiovascular diseases. In 2022, the U.S. FDA approved high-sensitivity troponin tests that enable more accurate detection of myocardial infarctions, helping to standardize practices across healthcare institutions. Additionally, point-of-care testing has gained traction due to its convenience, allowing for rapid assessment in emergency departments. The European Society of Cardiology updated its guidelines in 2021, highlighting the role of biomarkers in managing heart failure. Integration of artificial intelligence and machine learning into diagnostic processes has also begun, with firms like Siemens Healthineers exploring predictive algorithms to improve patient outcomes. Telemedicine's growth during the COVID-19 pandemic has further pushed demand for remote monitoring solutions, necessitating the development of portable biomarkers for widespread use. Moreover, decentralized trials, as advocated by regulatory bodies such as the FDA, are becoming common, facilitating real-world evidence gathering through remote patient monitoring. Such trends signify a shift toward personalized medicine, supported by biomarker innovation and regulatory frameworks that promote efficient healthcare delivery.

Future Opportunities

The landscape of the cardiac biomarkers market presents numerous opportunities spurred by ongoing technological advancements and regulatory frameworks. The European Medicines Agency's 2022 guidelines promote the integration of interoperability standards among diagnostic devices, which can boost collaboration between healthcare providers and technology companies. These standards pave the way for broader adoption of next-generation sequencing technologies, enhancing the precision of genetic testing related to cardiovascular diseases. Furthermore, companies such as Roche are currently focusing on developing multiplex tests that can simultaneously measure multiple biomarkers, which could streamline patient assessment processes. The expansion of telehealth services, accelerated by the pandemic, has increased the demand for remote patient monitoring solutions that utilize cardiac biomarkers for continuous assessment. Events such as the 2023 American College of Cardiology Scientific Session highlighted the growing role of digital health solutions in improving patient engagement and outcomes. Additionally, partnerships between pharmaceutical firms and diagnostic companies, like that of Novartis and Siemens Healthineers, are increasingly common, enabling the development of integrated solutions for personalized treatment. Regulatory initiatives, such as the FDA’s Breakthrough Device Program, are fostering faster access to innovative biomarkers, making it easier for companies to bring novel products to market.

Segmentation Analysis

By Type

The market is divided into subsegments including Creatine Kinase (CK-MB), Troponins T and I, Myoglobin, BNPs, IMA, and others. Troponins T and I accounted for the largest revenue share while myoglobin is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Troponins T and I

Market Share Leader

The subsegment with the largest revenue share in the market is Troponins T and I. This is due to the key role these proteins play in diagnosing heart attacks, due to their release into the blood stream during myocardial infarction. Early detection of heart conditions allows for immediate and effective treatment, driving demand for these proteins in clinical settings. Apart from the essential role they play in heart disease diagnosis, they're also used in the diagnosis of other conditions including chronic kidney disease and certain types of muscle damage. This further broadens their market. Troponin tests are mandated throughout the world in emergency departments, especially in developed economies with larger healthcare expenditure. Furthermore, a high incidence of cardiovascular disease globally supports demand. Regulatory bodies such as FDA, encourage the use of Troponin T and I tests for early and accurate diagnosis of myocardial infarction. Overarching factors such as these make Troponins T and I the largest revenue subsegment.

Fastest CAGR

Myoglobin

Forecast Period Growth Leader

Myoglobin, however, is anticipated to be the subsegment growing at the fastest CAGR during the forecast period. The key driver of this growth is the increasing recognition of the protein's role in early detection of heart attacks. Myoglobin is released into the bloodstream faster than Troponins T and I after the onset of a heart attack, making it a crucial factor in rapid diagnosis and treatment. Yet, it has been under-utilised due to historically lower specificity compared to Troponins T and I test. Recent advancements in testing technology and assays are improving its specificity, suggesting a potential rise in its adoption by clinicians. Additionally, emerging research is exploring role of myoglobin in other disease areas which could further fuel its demand. However, a primary barrier to adoption remains a lack of awareness among clinicians and limitations encompassing its non-specificity for myocardial infarction.

By Location of Testing

The Location of Testing market segment is divided into subsegments including Point of Care and Laboratory Testing. In 2024, Laboratory Testing accounted for the largest revenue share while Point of Care is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Laboratory Testing

Market Share Leader

Laboratory testing is the chief revenue-generating subsegment within the location of testing market. Several factors contribute to this dominance in 2024. Laboratories have a wide range of capabilities spanning from routine testing to highly specialized and complex testing. Lab tests can often help understand the inner workings of pathology, enabling accurate diagnosis of the patient's condition. Moreover, Laboratories are often equipped to support large volumes of testing, unlike the point of care facilities which traditionally have served a more on-demand, immediate testing requirement. Their capacity advantage directly translates to revenue advantage. Regulatory institutions globally also prefer laboratory testing results for critical matters, thereby driving the demand for these tests. The purchasing criteria primarily fronts accuracy, reliability, and comprehensive reports which laboratory tests excel at providing.

Fastest CAGR

Point of Care

Forecast Period Growth Leader

Point of care testing is the subsegment to watch for maximum growth in the coming years. Point of Care testing is characterized by the convenience and speed it offers. The tests are generally simple, allowing non-laboratory environments like home, office, school, or anywhere outside a traditional lab unit to perform these tests. Rapid technological advancements are major catalysts for this growth. Numerous start-ups and established corporations have invested in the development of point of care testing technologies, which in turn are becoming increasingly convenient and reliable. Another essential factor is the changing policy landscape favoring point of care testing for its ability to expedite healthcare delivery. However, there still exist barriers to adoption, primarily concerning the perceived reliability of testing and restrictions around certain types of testing.

By Application

The market is divided into subsegments including Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Atherosclerosis. Congestive Heart Failure accounted for the largest revenue share while Acute Coronary Syndrome is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Congestive Heart Failure

Market Share Leader

Congestive Heart Failure (CHF) continues to dominate the market, driven by factors such as increasing prevalence of heart disease globally, and the rising elderly population commonly suffering from this health condition. The adoption of beneficial medical lifestyle enhancements, along with technological advancements in the treatment and management of heart failure, has also fuelled its markedly larger share of revenue. Regulatory moves encouraging the adoption and coverage of effective treatments, as well as wider recognition of CHF within public health initiatives, have further spurred demand. The increasingly frequent application of CHF monitoring and management among healthcare providers also contributes to its leading status. As continued clinical emphasis on early detection and treatment becomes the focus, the demand for CHF related products and services is expected to grow even further.

Fastest CAGR

Acute Coronary Syndrome

Forecast Period Growth Leader

Acute Coronary Syndrome (ACS) is projected to be the fastest-growing subsegment in the market. The factors driving this growth include increasing global incidence of heart diseases, rising awareness about arterial diseases, and the emergence of new diagnostic technologies. The pivotal role of innovative and effective interventions and drugs in ACS treatment is a significant growth catalyst. Governments, healthcare providers, and key players in the healthcare market are engaged in partnerships aimed at boosting the development and adoption of ACS-related products, which is contributing to the growth trajectory of this subsegment. Nevertheless, the progressive emphasis on research and development, coupled with an expected increase in healthcare spending, promises a strong growth outlook for this subsegment.

Competitive Analysis

Key Market Players

Manufacturers / OEMs

Roche Diagnostics
Switzerland
Abbott Laboratories
US
Siemens Healthineers
Germany

Key Suppliers & Raw Materials

Thermo Fisher Scientific
US
Merck KGaA
Germany
Hoffmann-La Roche AG
Switzerland

Distributors, Integrators & Channel Partners

Henry Schein, Inc.
US
Cardinal Health
US
McKesson Corporation
US

Porter’s Five Forces Analysis

The following analysis provides insight into the competitive pressures in the Cardiac Biomarkers Market.

Supplier Bargaining Power

Medium

Concentrated supplier base but sensitive cardiac biomarker production process balances bargaining power.

Buyer Bargaining Power

Low

High switching costs and critical nature of products restrict buyers' negotiation power.

Threat of Substitutes

Low

Specialized product nature and necessity in cardiac care make substitution unlikely.

Threat of New Entrants

Medium

Regulatory barriers exist but growing cardiac diseases widens market entry possibilities.

Competitive Rivalry

High

Established players intensely compete with innovations and pricing strategies.

Regional Analysis

Geographic market dynamics and growth opportunities across key regions

Global Market Outlook

cardiac-biomarkers-market market regional share

North America

In 2024, North America's cardiac biomarkers market represented a critical segment in the region's diagnostic landscape.
Advancements in technology bolstered the demand, underlining improved precision in ischemic heart disease and acute coronary syndrome detection. Regulatory support, evidenced by U.S. Food and Drug Administration's approval of high-sensitivity troponin assays, served as another key driver by encouraging investments in research and development. Furthermore, increasing cardio-metabolic diseases incidences across the U.S., Canada, and Mexico spurned the need for accurate, prompt diagnostic measures, thereby fueling biomarker adoption.

Evolving patient awareness spurred changes in buyer behavior, with a noticeable lean toward preventive cardiac care, thus augmenting biomarker demand. Manufacturers responded accordingly with a shift in product development, focusing increasingly on multiplex biomarkers. This shift increased industry competition, instigating several mergers and acquisitions, such as Roche’s acquisition of Stratos Genomics, aimed at expanding capabilities. Diagnostic centers and hospitals emerged as the primary sectors utilizing cardiac biomarkers, owing to an increase in heart failure prevalence.
With technology adoption reshaping supply dynamics and rising health awareness altering buyer behavior, the cardiac biomarkers market in North America displayed a pattern of robust growth and innovation in 2024. This was particularly reflected within healthcare environments and regulatory bodies, punctuating their role in market progression.

Asia Pacific

In 2024, the Cardiac Biomarkers Market of Asia Pacific witnessed significant growth due to several attributing factors. Increased incidence of cardiovascular diseases, especially in highly populous countries like India and China, fueled the demand. Investment in healthcare infrastructure development by regional governments, particularly in Japan and key ASEAN capabilities like Thailand and Singapore, also contributed to the market expansion. South Korea and Australia demonstrated rapid adoption of advanced diagnostic technologies, thereby enhancing the supply dynamics in this sector.

The year saw a shift in buyer behavior, with hospitals and health centers prioritizing cardiac biomarkers tests for early detection of cardiac diseases. A recognizable trend was the growing number of strategic collaborations between diagnostic companies and research institutes, especially in China and India aimed at developing more accurate and cost-effective tests. Monitoring and enforcement of policies guiding the approval and usage of cardiac tests were more stringent, particularly in Japan and Australia—an indicator of market maturity. Emphasizing the importance of these biomarkers, retail pharmacies in South Korea and the broader ASEAN market increasingly stocked cardiac biomarker testing kits, facilitating easy access to diagnostic services. In conclusion, the cardiac biomarkers market was a significant segment of the healthcare sector in the Asia Pacific region in 2024.

Europe

The Cardiac Biomarkers Market in Europe in 2024 was dynamic, marked by evolving demand and numerous advancements. Drivers included an increase in cardiovascular diseases necessitating effective diagnostic tests triggering demand for cardiac biomarkers. Regulatory approvals, such as those of the European Medicines Agency (EMA), enhanced market credibility and potential adoption. Technology adoption was also expedited, with countries like Germany and the United Kingdom leveraging developments in proteomic and genomic profiling encouraging market growth. Moreover, the privatization of healthcare in Central and Eastern Europe increased investment in the sector, indirectly influencing market expansion.

The market witnessed several notable trends. Buyer behavior shifted towards advanced, rapid diagnostic tests, likely a response to the rising prevalence of heart diseases. The advent of next-generation technologies, particularly in Italy and Spain, indicated a shift towards high-sensitivity biomarker assays. In terms of channel dynamics, digital platforms were used extensively for knowledge dissemination pertaining to cardiac biomarker testing. Partnerships and M&A activities were prevalent, such as in the United Kingdom where healthcare providers and research institutions collaborated to advance cardiac biomarker research. Regulatory bodies across Europe, particularly France and the Nordics, enforced strict guidelines to ensure high-quality and reliable cardiac biomarker tests.

Latin America

In the base year of 2024, the Cardiac Biomarkers Market in Latin America experienced substantial development. Robust demand drivers include a growing prevalence of cardiovascular diseases coupled with an aging population particularly in Brazil and Mexico, leading to heightened awareness and increased testing. Investment in healthcare infrastructure, especially in Argentina and Colombia, was a significant factor, as it facilitated better accessibility to advanced diagnostic tests. Moreover, the adoption of newer technologies like high sensitivity cardiac troponin assays influenced the market positively.

Trends observed involve a shift in buyer preference towards automated biomarker tests for their enhanced accuracy and quick results. There was a notable preference for non-invasive diagnostic techniques in Chile and Peru. In addition, strategic partnerships among key players, such as that between Roche Diagnostics and Brazilian hospital Albert Einstein, were common. Enforcement of strict regulations by health authorities like ANVISA in Brazil and COFEPRIS in Mexico, aiming to ensure the quality and safety of these tests, also shaped the market landscape. The core customer base spanned across various sectors including hospitals, diagnostic labs, and ambulatory surgical centers. The use of Immunoassay in these sectors was dominant, largely due to its accuracy in the early detection of cardiac ailments. This clearly portrays the LATAM Cardiac Biomarkers Market in 2024, marked by technological adoption, strategic partnerships, and regulation adherence.

Middle East & Africa

In 2024, the cardiac biomarkers market witnessed significant growth in the Middle East and Africa due to increased prevalence of cardiovascular diseases, advancements in healthcare technology, and increased healthcare expenditure. Drivers for the growth include the escalating demand for early and accurate diagnosis in countries such as Saudi Arabia, United Arab Emirates, and Qatar due to rising incidence of heart diseases in these regions. Improved healthcare infrastructure, facilitated by government investment in countries like Egypt, South Africa, and Nigeria, further propelled the adoption of advanced cardiac biomarkers. Additionally, mandatory health insurance policies in the United Arab Emirates and Saudi Arabia boosted the affordability of cardiac care, thus increasing the usage of cardiac biomarkers. The growing acceptance of point-of-care testing in healthcare settings across the region expedited results and improved patient outcomes, supporting market growth.

On the trend front, the adoption of high sensitivity cardiac biomarkers for early detection of myocardial infarction was noted across Israel and Kenya. Public-Private partnerships in healthcare infrastructure development, particularly in South Africa and Nigeria, further fostered market growth. Lastly, the adoption of telemedicine in multiple countries, including Egypt and Qatar, enabled remote patient monitoring and increased utilization of cardiac biomarkers. These drivers and trends have collectively contributed to the progression of the cardiac biomarkers market in the Middle East and Africa.

Recent Industry Developments

Latest market innovations, product launches, and strategic initiatives

November 2025

Centers for Medicare & Medicaid Services (CMS) finalized the 2025 Physician Fee Schedule. The update mandates explicit Atherosclerotic Cardiovascular Disease (ASCVD) risk assessment coding, requiring multi-variable diagnostic reporting that includes cardiac biomarkers to qualify for full reimbursement.

May 2025

World Health Organization (WHO) launched the Global Diagnostics Coalition at the 78th World Health Assembly. This alliance coordinates public and private diagnostic players to expand infrastructure and stabilize supply lines for critical tests, specifically targeting high-sensitivity cardiac troponin assays in underserved regions.

January 2025

Abbott Laboratories secured U.S. FDA clearance for its Alere NT-proBNP assay on the automated Alinity i system. This launch expands high-throughput hospital lab menus to accelerate risk stratification and triage for patients with suspected heart failure.

Frequently Asked Questions

Recent Blogs

Key Strategies for Manufacturers to Capitalize on the Energy Storage Systems Market
Updated: Oct 28, 2025
VIEW
Navigating the Advanced Composites Market: A Comprehensive Guide for Suppliers and Distributors
Updated: Oct 28, 2025
VIEW
Decoding the Impact of Government Policies on the Global Electric Vehicle Market
Updated: Oct 28, 2025
VIEW

Recent News

Shandi Global Introduces ‘Chanza’ in India, Targeting High-Volume Foodservice and Institutional Nutrition Demand
Published: Oct 28, 2025
VIEW
Air Liquide Expands Its Presence in India With the Acquisition of NovaAir
Published: Oct 28, 2025
VIEW
Samsung Introduces 2025 Bespoke AI Appliance Lineup in India, Featuring Bespoke AI Laundry Combo
Published: Oct 28, 2025
VIEW